Physician profile
Allison Demany
NPI 1760904866
$1,794.58
in general payments reported to CMS, 2019-2025
16 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.64 · 2024: $601 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $472.79 | 2024-2025 | |
| Biogen, INC. | $189.12 | 2024-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $162.08 | 2024-2025 | Kisunla |
| Vanda Pharmaceuticals INC. | $152.87 | 2024 | Ponvory |
| Genzyme Corporation | $146.74 | 2025 | |
| Tg Therapeutics, INC. | $123.99 | 2025 | |
| Lundbeck LLC | $104.17 | 2025 | Vyepti |
| Genentech USA, INC. | $89.94 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Abbvie INC. | $65.40 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $62.92 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $56.89 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $40.92 | 2021-2025 | Rexulti |
| Ucb, INC. | $37.98 | 2025 | Briviact, Nayzilam |
| Ge Healthcare | $36.33 | 2025 | |
| Sk Life Science, INC. | $33.48 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Demany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.